No label defined (Q3250153)

From EU Knowledge Graph
Revision as of 13:45, 9 October 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in en)
Jump to navigation Jump to search
Project Q3250153 in Spain
Language Label Description Also known as
English
No label defined
Project Q3250153 in Spain

    Statements

    0 references
    10,000.0 Euro
    0 references
    20,000.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2019
    0 references
    31 December 2019
    0 references
    PROTOQSAR 2000 SL
    0 references
    0 references
    46190
    0 references
    LA LESIÓN HEPÁTICA INDUCIDA POR FÁRMACOS (DILI, POR SUS SIGLAS EN INGLÉS) HA SIDO REFERENCIADA COMO LA PRINCIPAL CAUSA DE DESGASTE DEL FÁRMACO TANTO DURANTE EL DESARROLLO CLÍNICO COMO POSTERIOR A LA APROBACIÓN, Y POR LO TANTO, DEBE CONSIDERARSE COMO UNO DE LOS PROBLEMAS DE SEGURIDAD CLAVE EN EL DESARROLLO DE NUEVOS FÁRMACOS. LA ELIMINACIÓN PREVENTIVA DE MOLÉCULAS QUE PROBABLEMENTE CAUSEN DAÑO HEPÁTICO EN LAS ETAPAS INICIALES DEL PROCESO DE DESCUBRIMIENTO DE FÁRMACOS REPRESENTA UNA ESTRATEGIA IMPORTANTE PARA LA REDUCCIÓN DEL COSTO TOTAL DEL DESARROLLO DE FÁRMACOS. LA EVALUACIÓN DE LA TOXICIDAD DE LOS PRODUCTOS QUÍMICOS REQUIERE EXPERIMENTOS CON ANIMALES, COSTOSOS, LARGOS Y ÉTICAMENTE CUESTIONABLES. COMO CONSECUENCIA, SE RECOMIENDA EL USO DE LOS RESULTADOS GENERADOS POR MÉTODOS ALTERNATIVOS, INCLUIDOS LOS MÉTODOS ESPECIALMENTE SIN PRUEBA (NTM), TAMBIÉN CONOCIDOS COMO HERRAMIENTAS DE SILICO. ENTRE ELLOS, LOS MÉTODOS DE ¿RELACIONES CUANTITATIVAS ESTRUCTURA-ACTIVIDAD¿ (QSAR) SON UNO DE LOS (Spanish)
    0 references
    LIVER INJURY INDUCED BY DRUGS (DILI FOR SHORT) HAS BEEN REFERENCED AS THE MAIN CAUSE OF WEAR DRUG BOTH DURING THE CLINICAL DEVELOPMENT AND POST-APPROVAL, AND THEREFORE MUST BE CONSIDERED AS ONE OF THE PROBLEMS KEY IN THE DEVELOPMENT OF NEW DRUGS SAFETY. PREVENTIVE REMOVAL OF MOLECULES LIKELY TO CAUSE LIVER DAMAGE IN THE INITIAL STAGES OF THE DRUG DISCOVERY PROCESS REPRESENTS AN IMPORTANT STRATEGY FOR REDUCING THE TOTAL COST OF DRUG DEVELOPMENT. THE EVALUATION OF THE TOXICITY OF CHEMICALS REQUIRES ANIMAL EXPERIMENTS, EXPENSIVE, LONG AND ETHICALLY QUESTIONABLE. CONSEQUENTLY, THE USE OF THE RESULTS GENERATED RECOMMENDED BY ALTERNATIVE METHODS, INCLUDING METHODS PARTICULARLY WITHOUT TEST (NTM), ALSO KNOWN AS TOOLS SILICO. AMONG THEM, THE METHODS OF ¿QUANTITATIVE STRUCTURE-ACTIVIDAD¿ RELATIONSHIPS (QSAR) ARE ONE OF THE MOST RECOGNIZED DRUG DESIGN, TOXICOLOGY, INDUSTRIAL AND ENVIRONMENTAL CHEMISTRY. TODAY, THEY CAN BE INCLUDED IN THE INTEGRATED TESTING STRATEGIES (ITS) TO PROVIDE INFORMATION (English)
    0 references
    Paterna
    0 references

    Identifiers

    20F01020101U_IVCI00000APEA9014
    0 references